Search Results - "Alarcon, Pedro A. de"

Refine Results
  1. 1

    Evaluation of angiogenic signaling molecules associated with reactive thrombocytosis in an iron-deficient rat model by Garcia, Jessica, Mankin, Peggy, Gnanamony, Manu, de Alarcon, Pedro A.

    Published in Pediatric research (01-08-2021)
    “…Background Iron deficiency anemia (IDA)-induced reactive thrombocytosis can occur in children and adults. The underlying mechanism for this phenomenon is…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    The contribution of telco data to fight the COVID-19 pandemic: Experience of Telefonica throughout its footprint by de Alarcon, Pedro A., Salevsky, Alejandro, Gheti-Kao, Daniel, Rosalen, Willian, Duarte, Marby C., Cuervo, Carlos, Muñoz, Jose J., Pascual, Juan M., Schurig, Martin, Treß, Thomas, Diaz, Elena, de la Cuesta, Carlos, Frias-Martinez, Enrique

    Published in Data & Policy (01-01-2021)
    “…The COVID-19 pandemic is a global challenge for humanity, in which a large number of resources are invested to develop effective vaccines and treatments. At…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Modeling Shape and Topology of Low-Resolution Density Maps of Biological Macromolecules by De-Alarcón, Pedro A., Pascual-Montano, Alberto, Gupta, Amarnath, Carazo, Jose M.

    Published in Biophysical journal (01-08-2002)
    “…In the present work we develop an efficient way of representing the geometry and topology of volumetric datasets of biological structures from medium to low…”
    Get full text
    Journal Article
  10. 10

    Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report by COLE, Peter D, SCHWARTZ, Cindy L, DRACHTMAN, Richard A, DE ALARCON, Pedro A, LU CHEN, TRIPPETT, Tanya M

    Published in Journal of clinical oncology (20-03-2009)
    “…The Children's Oncology Group conducted this phase II study to assess the efficacy and toxicity of gemcitabine and vinorelbine (GV) in pediatric patients with…”
    Get full text
    Journal Article
  11. 11

    SARS‐CoV‐2 vaccination response in pediatric oncology patients by D'Souza, Amber Marie, Thomas, Maria, Gnanamony, Manu, Nguyen, Thu Hien, Alarcon, Pedro A.

    Published in Pediatric blood & cancer (01-02-2024)
    “…Background There remains limited knowledge about the immune response to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccination in pediatric…”
    Get full text
    Journal Article
  12. 12
  13. 13

    A chemotherapy only therapeutic approach to pediatric Hodgkin lymphoma: AHOPCA LH 1999 by Castellanos, E. Mauricio, Barrantes, José Carlos, Báez, L. Fulgencio, Gamboa, Yessica, Peña, Armando, Alabi, Soad, Bonilla, Miguel, Wang, Huaping, Metzger, Monika L., de Alarcón, Pedro A.

    Published in Pediatric blood & cancer (01-06-2014)
    “…Background AHOPCA is a collaborative group that designs uniform treatment regimens (protocols) for children diagnosed with cancer in Central America. Based on…”
    Get full text
    Journal Article
  14. 14

    Development of the Hematopoietic System and Disorders of Hematopoiesis that Present During Infancy and Early Childhood by Fernández, Karen S., MD, de Alarcón, Pedro A., MD

    Published in The Pediatric clinics of North America (01-12-2013)
    “…This article reviews the ontogeny of hematopoiesis (embryonic/fetal/newborn phases) and its regulation and provides examples of the disorders of hematopoiesis…”
    Get full text
    Journal Article
  15. 15

    Late cognitive and adaptive outcomes of patients with neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia‐syndrome: A report from the Children's Oncology Group by Kumar, Prerna, Willard, Victoria W., Embry, Leanne, Naranjo, Arlene, LaBarre, Brian, Matthay, Katherine K., Alarcon, Pedro A.

    Published in Pediatric blood & cancer (01-07-2024)
    “…Background Opsoclonus‐myoclonus‐ataxia syndrome (OMAS) is a rare autoimmune disorder of the nervous system presenting with abnormal eye and limb movements,…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18

    Hu14.18K.322A Causes Direct Cell Cytotoxicity and Synergizes with Induction Chemotherapy in High-Risk Neuroblastoma by Thomas, Maria, Nguyen, Thu Hien, Drnevich, Jenny, D'Souza, Amber M, de Alarcon, Pedro A, Gnanamony, Manu

    Published in Cancers (30-05-2024)
    “…The disialoganglioside, GD2, is a promising therapeutic target due to its overexpression in certain tumors, particularly neuroblastoma (NB), with limited…”
    Get full text
    Journal Article
  19. 19
  20. 20